EVEROLIMUS

everolimus 5 mg tablet, 30

EVEROLIMUS (10131F)

everolimus 5 mg tablet, 30
10131F
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 30 # of repeats: 5 DPMQ: $902.17 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Afinitor